The development of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors such as ribociclib, abemaciclib, and palbociclib, revolutionized the management of metastatic ERα+ breast cancer, doubling progression-free survival on first-line therapy (16–18). Here, CDK4 is linked to breast carcinoma.